Karus Therapeutics is a clinical-stage biopharmaceutical company developing highly-selective small-molecule drugs for cancer patients with unmet medical needs and limited treatment options.
Location: United Kingdom, England
Employees: 11-50
Total raised: $7.6M
Founded date: 2005
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors |
| 07.09.2012 | Series B | $7.6M | - |
Mentions in press and media 4
| Date | Title | Description |
| 18.12.2012 | The Babraham Institute announces collaboration with Karus Therapeutics to explore PI3 Kinase | The Babraham Institute announces collaboration with Karus Therapeutics to explore PI3 Kinase 18-12-2012 The Babraham Institute and Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory dis... |
| 18.12.2012 | The Babraham Institute announces collaboration with Karus Therapeutics to explore PI3 Kinase | The Babraham Institute and Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, today announced that they have entered into a collaboration to further characterise nov... |
| 07.09.2012 | Karus Therapeutics Raises $7.6M First Tranche of Series B Funding | Karus Therapeutics, a Chilworth, UK-based developer of medicines for the treatment of inflammatory disease and cancer, has raised a $7.6m first tranche of a Series B funding. The round was led by new investors SV Life Sciences, New Leaf Ven... |
| 06.09.2012 | Karus Therapeutics Secures Series B Round | SOUTHAMPTON, ENGLAND, Leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, announces the closing of its Series B investment >> Click here for more funding data on Karus Therapeutic... |